Fig. 3From: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutationsChange in cancer-related symptoms while on treatment according to the investigator. (EOT: end of treatment)Back to article page